Beta Bionics, Inc. (BBNX)
Automate Your Wheel Strategy on BBNX
With Tiblio's Option Bot, you can configure your own wheel strategy including BBNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBNX
- Rev/Share 1.7981
- Book/Share 6.9516
- PB 2.4512
- Debt/Equity 0.0222
- CurrentRatio 14.6788
- ROIC -0.2004
- MktCap 740730896.0
- FreeCF/Share -1.4301
- PFCF -11.9367
- PE -10.0775
- Debt/Assets 0.0203
- DivYield 0
- ROE -0.4052
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BBNX | Truist | -- | Buy | -- | $26 | June 16, 2025 |
| Initiation | BBNX | Lake Street | -- | Buy | -- | $30 | June 12, 2025 |
| Initiation | BBNX | Wolfe Research | -- | Outperform | -- | $20 | May 30, 2025 |
| Initiation | BBNX | Goldman | -- | Neutral | -- | $16 | May 30, 2025 |
| Initiation | BBNX | Stifel | -- | Buy | -- | $25 | Feb. 24, 2025 |
| Initiation | BBNX | Leerink Partners | -- | Outperform | -- | $28 | Feb. 24, 2025 |
| Initiation | BBNX | Lake Street | -- | Buy | -- | $30 | Feb. 24, 2025 |
| Initiation | BBNX | BofA Securities | -- | Buy | -- | -- | Feb. 24, 2025 |
| Initiation | BBNX | Piper Sandler | -- | Overweight | -- | $26 | Feb. 24, 2025 |
| Initiation | BBNX | Robert W. Baird | -- | Neutral | -- | $20 | Feb. 20, 2025 |
News
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Beta Bionics, Inc. (NASDAQ:BBNX ) Q2 2025 Earnings Call July 29, 2025 4:30 PM ET Company Participants Blake Beber - Head of Investor Relations Sean T. Saint - President, CEO & Director Stephen H.
Read More
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.
Read More
Beta Bionics: Slowing Down Or Being Conservative?
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Negative
Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure.
Read More
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance.
Read More
About Beta Bionics, Inc. (BBNX)
- IPO Date 2025-01-30
- Website https://www.betabionics.com
- Industry Medical - Equipment & Services
- CEO Sean T. Saint PE
- Employees 352